Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
|Slideshows|April 17, 2018
April Research Update: Major Depressive Disorder
Author(s)Mark L. Fuerst
Relapse in MDD is associated with morphologic brain changes; stopping exercise may increase depressive symptoms; and inflammatory biomarkers may predict which treatment-resistant MDD patients benefit from ECT.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
2
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
3
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
4
Positive Phase 2 Topline Results: Remlifanserin for the Treatment of Alzheimer Disease Psychosis
5